Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MDGL 
Madrigal Pharmaceuticals Inc (MDGL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: MDGL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $512.43
1 Year Target Price $512.43
| 10 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.74% | Avg. Invested days 32 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.34B USD | Price to earnings Ratio - | 1Y Target Price 512.43 |
Price to earnings Ratio - | 1Y Target Price 512.43 | ||
Volume (30-day avg) 15 | Beta -1.03 | 52 Weeks Range 265.00 - 463.62 | Updated Date 11/2/2025 |
52 Weeks Range 265.00 - 463.62 | Updated Date 11/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12.67 |
Earnings Date
Report Date 2025-10-29 | When Before Market | Estimate -3.36 | Actual - |
Profitability
Profit Margin -54.68% | Operating Margin (TTM) -22.18% |
Management Effectiveness
Return on Assets (TTM) -18.31% | Return on Equity (TTM) -36.3% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9348957254 | Price to Sales(TTM) 18.11 |
Enterprise Value 9348957254 | Price to Sales(TTM) 18.11 | ||
Enterprise Value to Revenue 18.13 | Enterprise Value to EBITDA -8.32 | Shares Outstanding 22289014 | Shares Floating 10975779 |
Shares Outstanding 22289014 | Shares Floating 10975779 | ||
Percent Insiders 7.68 | Percent Institutions 107.8 |
Upturn AI SWOT
Madrigal Pharmaceuticals Inc
Company Overview
History and Background
Madrigal Pharmaceuticals Inc. was founded in 2006. It's a biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH). Key milestones include the development and clinical trials of resmetirom, a thyroid hormone receptor-u03b2 (THR-u03b2) selective agonist. The company has evolved from research to late-stage clinical development and regulatory submissions.
Core Business Areas
- NASH Therapeutics Development: Focuses on the research, development, and commercialization of resmetirom for the treatment of NASH. This includes conducting clinical trials, regulatory submissions, and preparing for potential commercial launch.
Leadership and Structure
Bill Sibold serves as Chief Executive Officer. The company has a board of directors and operates with a functional organizational structure focused on research and development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- Resmetirom: Resmetirom is Madrigal's lead product candidate for the treatment of NASH. Currently awaiting FDA approval (March 14, 2024). As a first-in-class therapy, it aims to address a significant unmet medical need. No current market share as it is not yet approved. Competitors will include other potential NASH therapies from companies like Viking Therapeutics (VKTX) and Akero Therapeutics (AKRO), once they are approved.
Market Dynamics
Industry Overview
The NASH market is a large and growing pharmaceutical area with no approved therapies until potentially now with Resmetirom. It targets individuals with liver inflammation and fibrosis due to fat accumulation. The market is characterized by high unmet need and significant commercial potential.
Positioning
Madrigal Pharmaceuticals is positioned as a potential leader in the NASH market with resmetirom. Its THR-u03b2 selective agonist mechanism of action gives it a competitive advantage. It has reached advanced stages of clinical trials and regulatory submission.
Total Addressable Market (TAM)
The estimated TAM for NASH therapies is significant, potentially exceeding $35 billion annually. Madrigal is well-positioned to capture a substantial portion of this market with the first FDA approval of a therapy for NASH.
Upturn SWOT Analysis
Strengths
- First-mover advantage in NASH market with resmetirom
- Positive clinical trial data for resmetirom
- Strong intellectual property position
- Experienced management team
Weaknesses
- Reliance on a single product candidate
- Risk associated with regulatory approval
- High cash burn rate
- Limited commercial infrastructure prior to potential approval
Opportunities
- Expansion into other liver disease indications
- Partnerships and collaborations with other pharmaceutical companies
- Potential for premium pricing due to unmet need
- Further data collection to improve clinical confidence
Threats
- Competition from other NASH therapies in development
- Regulatory setbacks or delays
- Pricing pressures from payers
- Unfavorable changes in the healthcare landscape
Competitors and Market Share
Key Competitors
- VKTX
- AKRO
Competitive Landscape
The competitive landscape is evolving rapidly. Madrigal's potential first-mover advantage is a key strength. Competitors are developing therapies with different mechanisms of action, creating a diversified approach to addressing NASH. *Note: As no products are yet approved for the treatment of NASH, market shares are zero.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as the company has been primarily focused on R&D. Future growth depends on the successful commercialization of resmetirom.
Future Projections: Analyst estimates project significant revenue growth if resmetirom is approved. Revenue projections vary based on market penetration and pricing strategies. Estimates range from $500 million to $2 billion in peak sales.
Recent Initiatives: Recent initiatives include regulatory submissions to the FDA and EMA, preparation for commercial launch, and continued clinical trials.
Summary
Madrigal Pharmaceuticals is highly dependent on the FDA approval of resmetirom for NASH, and is positioned as a potential market leader due to being potentially first to market with an approved therapy. The company's high cash burn rate and reliance on a single product are risk factors. Successful commercialization of resmetirom will be critical for long-term growth. Competition from other therapies in development remains a key threat.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Madrigal Pharmaceuticals Inc. SEC Filings
- Analyst Reports
- Company Press Releases
- ClinicalTrials.gov
- Company Website
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market share data is estimated and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Madrigal Pharmaceuticals Inc
Exchange NASDAQ | Headquaters West Conshohocken, PA, United States | ||
IPO Launch date 2007-02-06 | CEO, President & Director Mr. William J. Sibold | ||
Sector Healthcare | Industry Biotechnology | Full time employees 528 | Website https://www.madrigalpharma.com |
Full time employees 528 | Website https://www.madrigalpharma.com | ||
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.